• research development hartington4

Hartington along the years

 

1996

Hartington Business S.L. is founded in Spain.

 

 
 

1998

Iveriapharma is founded in Georgia, enabling the clinical trials for Sinuforte® to start.

 

 

 

 

 

 

 
 

2003

Favourable results from the preclinical trials; clinical trials on the treatment of herpes are initiated.

 

2005

Launch of Sinuforte® in Russia.

 

 

 

2007

Enters the pharmaceutical market of the following countries: Germany, Poland, and Slovenia. Hartington Pharma Ltd is set up for the manufacture of Nasodren®.

 

 

 

2010

Introduction of Nasodren® in more new markets: the Netherlands, Luxemburg, Czech Republic, Baltic countries and Austria. Introduction of the consumer corporate campaign.

 

2012

Introduction of Nasodren® in Belgium, France, Switzerland, Sweden and Croatia.

 

2014

Launch of Nasodren® in Turkmenistan and Spain.

 

 

1997

Work is started on a compound to cure rhinosinusitis.

 
 

2002

Construction of new production plant in Georgia is completed, equipped with the latest production lines and the most advanced manufacturing resources. Investigation into the treatment of herpes is initiated.

Introduction of Nasodren® (Sinuforte®) in Georgia, Azerbaijan, Ukraine, Kazakhstan and Belarus.

 

2004

Hartington Pharmaceutical S.L. is founded in Spain.

 

 

2006

Hartington enters the Western European pharmaceutical market with the Spanish Licence for Fluirespira Forte® from Zambon Group.

 

2009

Important documents released such as US clinical trial (434-083) conclusion, Nasodren® monograph, newsletter, consumer focus, Nasodren® web page, sales folder. Expansion of Nasodren® to new countries such as Greece, Romania and Bulgaria.

 

2011

Launch of Nasodren® in Australia and Arabia Saudi.

 

 

 

2013

Launch of Nasodren® in Serbia and Finland.